Berkshire Hathaway Inc. (BRK-B) Stock: Completes $9.7B OxyChem Deal as Post-Buffett Era Begins

TLDR

• Berkshire Hathaway completed its $9.7 billion OxyChem acquisition.
• The deal strengthens Berkshire’s chemicals and industrial exposure.
• Occidental plans to use proceeds to cut debt below $15 billion.
• Greg Abel officially takes over as CEO in the post-Buffett era.
• Berkshire holds a record $381.7 billion cash pile.

Berkshire Hathaway Inc. ($BRK-B) stock traded at $494.06, down 1.71%, as the conglomerate confirmed the completion of its $9.7 billion acquisition of Occidental Chemical Corporation, widely known as OxyChem.

Berkshire Hathaway Inc., BRK-B

The transaction closed on January 2, 2026, marking one of Berkshire’s largest recent deals and coinciding with the start of its post-Buffett leadership era.

The all-cash acquisition was first announced in October 2025, with Berkshire agreeing to buy OxyChem from Occidental Petroleum Corporation. The purchase price remains subject to customary adjustments, though Berkshire stated it had sufficient cash on hand to fund the deal and cover all related expenses.

Details of the OxyChem Acquisition

Under the terms of the agreement, an Occidental subsidiary retained OxyChem’s legacy environmental liabilities, while Glenn Springs Holdings continues to manage existing remediation projects for that unit. OxyChem itself will operate under Berkshire ownership with continuity in leadership, as Wade Alleman remains president and CEO.

The transaction required regulatory approvals and standard closing conditions, all of which were satisfied ahead of the expected fourth-quarter timeline. Barclays Capital served as financial advisor to Occidental, while legal counsel included Cravath, Swaine & Moore for Occidental and Kirkland & Ellis for Berkshire.

For Occidental, the sale represents a balance sheet reset. The company expects to use $6.5 billion of the proceeds to reduce debt, targeting principal debt below $15 billion. This move supports Occidental’s efforts to strengthen its financial position after years of heavy capital spending.

Strategic Fit for Berkshire Hathaway

OxyChem adds a large-scale chemicals business to Berkshire’s already diverse portfolio, which spans insurance, railroads, energy, manufacturing, and consumer brands. The acquisition fits Berkshire’s long-standing approach of buying established, cash-generating businesses with durable market positions.

While Berkshire has trimmed stakes in longtime holdings such as Apple and Bank of America, the OxyChem deal underscores that the conglomerate remains willing to deploy capital into operating businesses when valuations and strategic fit align.

Despite the size of the transaction, some investors view it as modest relative to Berkshire’s scale. With a market value exceeding $1 trillion and limited opportunities that can materially shift earnings, even multi-billion-dollar acquisitions may not “move the needle” in the short term.

Entering the Post-Buffett Era

The completion of the OxyChem deal comes as Berkshire transitions leadership. Warren Buffett has handed the CEO role to Greg Abel after six decades at the helm, marking a historic shift for the company. Buffett remains chairman and has said he plans to stay active in supporting Abel from Berkshire’s Omaha office.

Abel, 63, joined Berkshire in 2000 following the acquisition of MidAmerican Energy, now Berkshire Hathaway Energy. He has overseen non-insurance operations since 2018, giving him deep familiarity with the company’s sprawling business lines.

Market reaction to the transition has been muted. Class B shares edged lower even as broader U.S. equity indexes posted gains, reflecting investor caution during a symbolic moment for the conglomerate.

Cash Position and Capital Allocation

One of Abel’s defining challenges will be capital deployment. Berkshire held $381.7 billion in cash and equivalents as of September 30, a record level that has sparked debate among shareholders. While the cash provides flexibility and downside protection, it also highlights the scarcity of large, attractive acquisition targets.

Berkshire shares underperformed the S&P 500 in 2025, adding pressure on new leadership to demonstrate that the company can sustain its long-term track record without Buffett as CEO.

Stock Performance Context

As of January 2, 2026, BRK-B shares showed mixed performance across time frames. The stock posted a 9.55% gain over the past year but lagged the S&P 500. Over five years, Berkshire outperformed the benchmark, reflecting the durability of its diversified model.

For investors, the OxyChem acquisition and leadership transition signal continuity rather than reinvention. Berkshire remains a conservative, cash-rich conglomerate focused on long-term value, even as it navigates a new chapter without the daily leadership of the “Oracle of Omaha.”

The post Berkshire Hathaway Inc. (BRK-B) Stock: Completes $9.7B OxyChem Deal as Post-Buffett Era Begins appeared first on CoinCentral.